Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: A prospective cohort study

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Mukonzo, Jackson K ^a,b   Okwera, Alphonse ^b   Nakasujja, Neoline ^b   Luzze, Henry ^b   Sebuwufu, Deogratious ^b   Ogwal Okeng, Jasper ^b   Waako, Paul ^b   Gustafsson, Lars L ^a   Aklillu, Eleni ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MAKERERE UNIVERSITY   (Uganda)

Author keywords

Antiretroviral therapy; CNS; CYP2B6; Efavirenz; HIV; Neuropsychiatric toxicity; Rifampicin; Tuberculosis; Ugandans

Indexed keywords

CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 3A5; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; LAMIVUDINE PLUS ZIDOVUDINE; MULTIDRUG RESISTANCE PROTEIN 1; PYRAZINAMIDE; RIFAMPICIN;

ABCB1 GENE; ADULT; ANTIBIOTIC THERAPY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; CONCURRENT INFECTION; CONTROLLED STUDY; CYP2A6 GENE; CYP2B6 GENE; CYP3A5 GENE; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HALLUCINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NR1I3 GENE; PHARMACOGENETICS; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SCORING SYSTEM; SEX DIFFERENCE; SLEEP DISORDER; SLEEP WALKING; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; UGANDA;

ADULT; ANTI-HIV AGENTS; ANTIBIOTICS, ANTITUBERCULAR; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; CYTOCHROME P-450 CYP3A; FEMALE; GENE FREQUENCY; HALLUCINATIONS; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEMORY DISORDERS; MENTAL DISORDERS; MILD COGNITIVE IMPAIRMENT; PROSPECTIVE STUDIES; RIFAMPIN; SLEEP AROUSAL DISORDERS; TUBERCULOSIS; UGANDA;

EID: 84878378977     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-261     Document Type: Article

References (61)

1. McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap. Ann Neurol 2010, 67:699-714.
2. Robertson K, Liner J, Meeker RB. Antiretroviral neurotoxicity. J Neurovirol 2012, 18:388-399. 10.1007/s13365-012-0120-3, 22811264.
3. Elzi L, Marzolini C, Furrer H, Ledergerber B, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Weber R, Battegay M. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 2010, 170:57-65. 10.1001/archinternmed.2009.432, 20065200.
4. Schouten JT, Krambrink A, Ribaudo HJ, Kmack A, Webb N, Shikuma C, Kuritzkes DR, Gulick RM. Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095. Clin Infect Dis 2010, 50:787-791. 10.1086/650539, 2975665, 20121419.
5. Ward DJ, Curtin JM. Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. AIDS Patient Care STDS 2006, 20:542-548. 10.1089/apc.2006.20.542, 16893323.
6. Tashima KT, Caliendo AM, Ahmad M, Gormley JM, Fiske WD, Brennan JM, Flanigan TP. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J Infect Dis 1999, 180:862-864. 10.1086/314945, 10438381.
7. Best BM, Koopmans PP, Letendre SL, Capparelli EV, Rossi SS, Clifford DB, Collier AC, Gelman BB, Mbeo G, McCutchan JA, et al. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother 2011, 66:354-357. 10.1093/jac/dkq434, 3019085, 21098541.
8. Kenedi CA, Goforth HW. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav 2011, 15:1803-1818. 10.1007/s10461-011-9939-5, 21484283.
9. Clifford DB, Evans S, Yang Y, Acosta EP, Goodkin K, Tashima K, Simpson D, Dorfman D, Ribaudo H, Gulick RM. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005, 143:714-721. 10.7326/0003-4819-143-10-200511150-00008, 16287792.
10. Jena A, Sachdeva RK, Sharma A, Wanchu A. Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: a 24-week prospective study. J Int Assoc Physicians AIDS Care (Chic) 2009, 8:318-322.
11. Perez-Molina JA. Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clin Trials 2002, 3:279-286. 10.1310/3Q91-YT2D-BUT4-8HN6, 12187501.
12. Rihs TA, Begley K, Smith DE, Sarangapany J, Callaghan A, Kelly M, Post JJ, Gold J. Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study. HIV Med 2006, 7:544-548. 10.1111/j.1468-1293.2006.00419.x, 17105514.
13. Scourfield A, Zheng J, Chinthapalli S, Waters L, Martin T, Mandalia S, Nelson M. Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals. AIDS 2012, 26:1399-1401. 10.1097/QAD.0b013e328353b047, 22441251.
14. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 2003, 306:287-300. 10.1124/jpet.103.049601, 12676886.
15. Ogburn ET, Jones DR, Masters AR, Xu C, Guo Y, Desta Z. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos 2010, 38:1218-1229. 10.1124/dmd.109.031393, 2908985, 20335270.
16. Ngaimisi E, Mugusi S, Minzi OM, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, et al. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther 2010, 88:676-684. 10.1038/clpt.2010.172, 20881953.
17. Miller DS, Bauer B, Hartz AM. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev 2008, 60:196-209. 10.1124/pr.107.07109, 2634288, 18560012.
18. Dirson G, Fernandez C, Hindlet P, Roux F, German-Fattal M, Gimenez F, Farinotti R. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier. Pharm Res 2006, 23:1525-1532. 10.1007/s11095-006-0279-5, 16779703.
19. Mukonzo JK, Roshammar D, Waako P, Andersson M, Fukasawa T, Milani L, Svensson JO, Ogwal-Okeng J, Gustafsson LL, Aklillu E. A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol 2009, 68:690-699. 10.1111/j.1365-2125.2009.03516.x, 2791975, 19916993.
20. Swart M, Ren Y, Smith P, Dandara C. ABCB1 4036A>G and 1236C>T Polymorphisms Affect Plasma Efavirenz Levels in South African HIV/AIDS Patients. Front Genet 2012, 3:236. 3488761, 23133441.
21. Ngaimisi E, Habtewold A, Minzi O, Makonnen E, Mugusi S, Amogne W, Yimer G, Riedel K, Janabi M, Aderaye G, et al. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: A parallel-group prospective cohort study in two Sub-Saharan African populations. PLoS One 2013,
22. Elens L, Vandercam B, Yombi JC, Lison D, Wallemacq P, Haufroid V. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics 2010, 11:1223-1234. 10.2217/pgs.10.94, 20860463.
23. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002, 359:30-36. 10.1016/S0140-6736(02)07276-8, 11809184.
24. Faucette SR, Zhang TC, Moore R, Sueyoshi T, Omiecinski CJ, LeCluyse EL, Negishi M, Wang H. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 2007, 320:72-80.
25. Habtewold A, Amogne W, Makonnen E, Yimer G, Riedel KD, Ueda N, Worku A, Haefeli WE, Lindquist L, Aderaye G, et al. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J Antimicrob Chemother 2011, 66:2350-2361. 10.1093/jac/dkr304, 21846671.
26. Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 2009, 23:2101-2106. 10.1097/QAD.0b013e3283319908, 2875867, 19779319.
27. Nunez M, Gonzalez de Reqeuna D, Gallego L, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr 2001, 28:399-400.
28. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001, 15:71-75. 10.1097/00002030-200101050-00011, 11192870.
29. Pozniak AL, Miller RF, Lipman MC, Freedman AR, Ormerod LP, Johnson MA, Collins S, Lucas SB. BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005. HIV Med 2005, 6(Suppl 2):62-83.
30. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Alarcon-Gonzalez A, Gomez-Mateos J, Leon-Jimenez E, Sarasanacenta M, Lopez-Pua Y, Pachon J. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 2002, 41:681-690. 10.2165/00003088-200241090-00004, 12126459.
31. Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Kumar P, Ramesh K, Anitha S, Narendran G, Menon P, Gomathi C, Swaminathan S. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. Antimicrob Agents Chemother 2009, 53:863-868. 10.1128/AAC.00899-08, 2650539, 19124658.
32. Cohen K, Grant A, Dandara C, McIlleron H, Pemba L, Fielding K, Charalombous S, Churchyard G, Smith P, Maartens G. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 2009, 14:687-695.
33. Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, et al. Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis. Clin Pharmacol Ther 2011, 90:406-413. 10.1038/clpt.2011.129, 21814190.
34. Gutierrez F, Navarro A, Padilla S, Anton R, Masia M, Borras J, Martin-Hidalgo A. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 2005, 41:1648-1653. 10.1086/497835, 16267739.
35. Kass JS, Shandera WX. Nervous system effects of antituberculosis therapy. CNS Drugs 2010, 24:655-667. 10.2165/11534340-000000000-00000, 20658798.
36. Reeves RR, Liberto V. Confusion associated with isoniazid-induced pyridoxine deficiency. Psychosomatics 2004, 45:537-538. 10.1176/appi.psy.45.6.537, 15546832.
37. Alao AO, Yolles JC. Isoniazid-induced psychosis. Ann Pharmacother 1998, 32:889-891. 10.1345/aph.17377, 9762376.
38. Citak A, Kaya O, Ucsel R, Karabocuoglu M, Uzel N. Acute isoniazid neurotoxicity in childhood. Turk J Pediatr 2002, 44:54-57.
39. Brennan-Benson P, Lyus R, Harrison T, Pakianathan M, Macallan D. Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. AIDS 2005, 19:1541-1543. 10.1097/01.aids.0000183519.45137.a6, 16135909.
40. Burger D, van der Heiden I, La Porte C, van der Ende M, Groeneveld P, Richter C, Koopmans P, Kroon F, Sprenger H, Lindemans J, et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol 2006, 61:148-154. 10.1111/j.1365-2125.2005.02536.x, 1885008, 16433869.
41. Wyen C, Hendra H, Siccardi M, Platten M, Jaeger H, Harrer T, Esser S, Bogner JR, Brockmeyer NH, Bieniek B, et al. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J Antimicrob Chemother 2011, 66:2092-2098. 10.1093/jac/dkr272, 21715435.
42. Gounden V, van Niekerk C, Snyman T, George JA. Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res Ther 2010, 7:32. 10.1186/1742-6405-7-32, 2933581, 20723261.
43. Seydi M, Diop SA, Dieng AB, Tekpa G, Soumare M, Diouf A, Niang K, Lakh A, Ndiaye I, Fall MB, et al. Tolerance study of a triple first-line antiretroviral combination zidovudine, lamivudine and efavirenz in Dakar, Senegal. Bull Soc Pathol Exot 2009, 102:99-100.
44. Aklillu E, Dandara C, Bertilsson L, Masimirembwa C. Pharmacogenetics of Cytochrome P450s in African Populations: Clinical and Molecular Evolutionary Implications. Pharmacogenomics in Admixed Populations 2007, 99-119. Austin, TX: Landes Bioscience, Suarez-Kurtz G.
45. Jamshidi Y, Moreton M, McKeown DA, Andrews S, Nithiyananthan T, Tinworth L, Holt DW, Sadiq ST. Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection. J Antimicrob Chemother 2010, 65:2614-2619. 10.1093/jac/dkq369, 20952418.
46. Folstein MF, Folstein SE, McHugh PR. " Mini-mental state" A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198. 10.1016/0022-3956(75)90026-6, 1202204.
47. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007, 69:1789-1799. 10.1212/01.WNL.0000287431.88658.8b, 17914061.
48. Tozzi V, Balestra P, Galgani S, Narciso P, Ferri F, Sebastiani G, D'Amato C, Affricano C, Pigorini F, Pau FM, et al. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. AIDS 1999, 13:1889-1897. 10.1097/00002030-199910010-00011, 10513647.
49. Tozzi V, Balestra P, Salvatori MF, Vlassi C, Liuzzi G, Giancola ML, Giulianelli M, Narciso P, Antinori A. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr 2009, 52:56-63. 10.1097/QAI.0b013e3181af83d6, 19731418.
50. Efavirenz (Sustiva). Res Initiat Treat Action 2000, 6:22-23.
51. Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, Abrahams M, Goemaere E, Coetzee D, Maartens G. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008, 300:530-539. 10.1001/jama.300.5.530, 18677025.
52. Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, Burapatarawong S, Thongyen S, Likanonsakul S, Thawornwa U, et al. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis 2009, 48:1752-1759. 10.1086/599114, 19438397.
53. Ren Y, Nuttall JJ, Eley BS, Meyers TM, Smith PJ, Maartens G, McIlleron HM. Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 2009, 50:439-443. 10.1097/QAI.0b013e31819c33a3, 19223781.
54. McIlleron H, Schomaker M, Ren Y, Sinxadi P, Nuttall JJ, Gous H, Moultrie H, Eley B, Merry M, Smith P, et al. Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype. AIDS 2013,
55. Gengiah TN, Holford NH, Botha JH, Gray AL, Naidoo K, Abdool Karim SS. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. Eur J Clin Pharmacol 2012, 68:689-695. 10.1007/s00228-011-1166-5, 22108776.
56. Kwara A, Lartey M, Sagoe KW, Court MH. Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. AIDS 2011, 25:388-390. 10.1097/QAD.0b013e3283427e05, 21150552.
57. Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, Swindells S, Benson CA, Grinsztejn B, Sanne IM, Havlir DV, et al. Relationship between weight, efavirenz exposure and virologic suppression in HIV-infected patients on rifampin-based TB treatment in the ACTG A5221 STRIDE study. Clin Infect Dis 2013, May 20. [Epub ahead of print].
58. Orrell C, Cohen K, Conradie F, Zeinecker J, Ive P, Sanne I, Wood R. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?. Antivir Ther 2011, 16:527-534. 10.3851/IMP1780, 3145153, 21685540.
59. Guo N, Marra F, Fitzgerald JM, Elwood RK, Marra CA. Impact of adverse drug reaction and predictivity of quality of life status in tuberculosis. Eur Respir J 2010, 36:206-208. 10.1183/09031936.00159409, 20595167.
60. Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, Motsinger-Reif AA, Ritchie MD, Zanger UM, Acosta EP, Morse GD, et al. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis 2010, 202:717-722. 10.1086/655470, 2919241, 20662624.
61. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004, 18:2391-2400.